Probing multidrug resistance P-glycoprotein transporter activity with SPECT radiopharmaceuticals

Current Topics in Medicinal Chemistry

Volumn 10, Issue 17, 2010, Pages 1834-1845

  Piwnica Worms, David ^a,b   Sharma, Vijay ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABC transporters; Blood brain barrier; Cancer; Gene therapy; Metal complexes; Multidrug resistance; P glycoprotein; PET; Radiopharmaceuticals; SPECT; Technetium 99m

Indexed keywords

BIRICODAR; GLYCOPROTEIN P; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN 1; RADIOPHARMACEUTICAL AGENT; TARIQUIDAR; TECHNETIUM 99M; VALSPODAR; ZOSUQUIDAR;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD TESTIS BARRIER; CANCER GENE THERAPY; CELL STRAIN MCF 7; CREUTZFELDT JAKOB DISEASE; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; DRUG DISPOSITION; GENETIC POLYMORPHISM; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR IMAGING; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NONHUMAN; PARKINSON DISEASE; PHYSICAL CHEMISTRY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR PROBES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS; NEURODEGENERATIVE DISEASES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 77958016911     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610792928086     Document Type: Article

References (141)

1. Higley, B.; Smith, F.W.; Smith, T.; Gemmell, H.G.; Gupta, P.D.; Gvozdanovic DV, Graham D, Hinge D, Davidson J, Lahiri A, Technetium-99m-1,2-bis[bis(2-ethoxyethyl)phosphino]ethane, human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J. Nucl. Med., 1993, 34, 30-38.
2. Ling, V.; Thompson, L.H. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J. Cell Physiol., 1974, 83, 103-111.
3. Gerlach, J.H.; Endicott, J.A.; Juranka, P.F.; Henderson, G.; Sarangi, F.; Deuchars, K. L.; Ling, V. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature, 1986, 324,485-489.
4. Gros, P.; Ben Neriah, Y.; Croop, J.M.; Housman, D.E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature, 1986, 323, 728-731.
5. Endicott, J.A.; Ling, V. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu. Rev. Biochem., 1989, 58,137-171.
6. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem., 1993, 62, 385-427.
7. Gottesman, M.; Fojo, T.; Bates, S. Multidrug resistance in cancer, role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2, 48-58.
8. Bosch, I.; Croop, J. P-glycoprotein multidrug resistance and cancer. Biochim. Biophys. Acta, 1996, 1288, F37-F54.
9. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters, the multidrug resistance-associated proteins. J. Natl. Cancer Inst., 2000, 92, 1295-1302.
10. Kruh, G.; Belinsky, M. The MRP family of drug efflux pumps. Oncogene, 2003, 22, 7537-7552.
11. Ambudkar, S.; Dey, S.; Hrycyna, C.; Ramachandra, M.; Pastan, I.; Gottesman, M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 361-398.
12. Ames, G. Bacterial periplasmic transport systems, structure, mechanism and evolution. Annu. Rev. Biochem., 1986, 55, 397-425.
13. Gros, P.; Dhir, R.; Croop, J.; Talbot, F. A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc. Natl. Acad. Sci. USA, 1991, 88, 7289-7293.
14. Bruggemann, E.P.; Germann, U.A.; Gottesman, M.M.; Pastan, I. Two different regions of phosphoglycoprotein are photoaffinitylabeled by azidopine. J. Biol. Chem., 1989, 264, 15483-15488.
15. Yoshimura, A.; Kuwazuru, Y.; Sumizawa, T.; Ichikawa, M.; Ikeda, S.; Uda, T.; Akiyama, S. J. Biol. Chem., 1990, 264, 16282.
16. Raviv, Y.; Pollard, H.; Bruggemann, E.; Pastan, I.; Gottesman, M. J. Biol. Chem., 1990, 265, 3975.
17. Rosenberg, M.; Callaghan, R.; Modok, S.; Higgins, C. Three dimensional structure of P-glycoprotein. J. Biol. Chem., 2005, 280, 2857-2862.
18. Higgins, C.; Linton, K. The ATP switch model for ABC transporters. Nat. Struct. Mol. Biol., 2004, 11, 918-926.
19. Aller, S.G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell P.M.; Trinh, Y.T.; Zhang, Q.; Urbatsch, I.L. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science, 2009, 323, 1718-1722.
20. Gottesman, M.M.; Ambudkar, S.V.; Xia, D. Structure of a multidrug transporter. Nat. Biotechnol., 2009, 27, 546-547.
21. Franke, R.M.; Gardner, E.R.; Sparreboom, A. Pharmacogenetics of Drug Transporters. Curr. Pharm. Des., 2009.
22. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M.M.; Pastan, I.; Willingham, M.C. Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA, 1987, 84, 7735-7738.
23. Hitchins, R.N.; Harman, D.H.; Davey, R.A.; Bell, D.R. Identification of a multidrug resistance associated antigen (P-glycoprotein) in normal human tissues. Eur. J. Cancer Clin. Oncol., 1988, 24, 449-454.
24. Cordon-Cardo, C.; OBrien, J.; Casals, D.; Rittman, G.; Biedler, J.; Melamed, M.; Bertino, J. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA, 1989, 86, 695-698.
25. Rao, V.; Dahlheimer, J.; Bardgett, M.; Snyder, A.; Finch, R.; Sartorelli, A.; Piwnica-Worms, D. Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal fluid drug-permeability barrier. Proc. Natl. Acad. Sci. USA, 1999, 96, 3900-3905.
26. Croop, J.M.; Raymond, M.; Haber, D.; Devault, A.; Arceci, R.J.; Gros, P.; Housman, D.E. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol. Cell Biol., 1989, 9,1346-1350.
27. Staud, F.; Ceckova, M.; Micuda, S.; Pavek, P. Expression and function of p-glycoprotein in normal tissues, effect on pharmacokinetics. Methods Mol. Biol., 2010, 596,199-222.
28. Cascorbi, I.; Haenisch, S. Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol. Biol., 2010, 596, 95-121.
29. Germann, U.A.; Willingham, M.C.; Pastan, I.; Gottesman, M.M. Expression of the human multidrug transporter in insect cells by a recombinant baculovirus. Biochemistry, 1990, 29, 2295-2303.
30. Ahmad, S.; Safa, A.R.; Glazer, R.I. Modulation of P-glycoprotein by protein kinase C in a baculovirus expression system. Biochemistry, 1994, 33, 10313-10318.
31. Homolya, L.; Hollo, Z.; Germann, U.A.; Pastan, I.; Gottesman, M.M.; Sarkadi, B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem., 1993, 268, 21493-21496.
32. Abrams, M.A.; Davison, A.; Jones, A.G.; Costello, C.E.; Pang, H. Synthesis and characterization of hexakis(alkyl isocyanide) and hexakis(arylisocyanide) complexes of technetium(I). Inorg. Chem., 1983, 22, 2798-2800.
33. Wackers, F.J.; Berman, D.; Maddahi, J.; Beller, G.; Straus, H.; Boucher, C.; Picard, M.; Holman, B.; Fridrich, R. Tc-99m-hexakis 2-methoxy isobutylisonitrile, human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J. Nucl. Med., 1989, 30, 301-309.
34. Piwnica-Worms, D.; Chiu, M.; Budding, M.; Kronauge, J.; Kramer, R.; Croop, J. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res., 1993, 53, 977-984.
35. 6Cl and its hydrolysis products. Inorg. Chem., 1991, 30, 4265-4271.
36. Piwnica-Worms, D.; Kronauge, J.; Chiu, M. Uptake and retention of hexakis (2-methoxy isobutyl isonitrile) technetium(I) in cultured chick myocardial cells, mitochondrial and plasma membrane potential dependence. Circulation, 1990, 82, 1826-1838.
37. Backus, M.; Piwnica-Worms, D.; Hockett, D.; Kronauge, J.; Lieberman, M.; Ingram, P.; LeFurgey, A. Microprobe analysis of Tc-MIBI in heart cells, calculation of mitochondrial potential. Am. J. Physiol., (Cell) 1993, 265, C178-C187.
38. Piwnica-Worms, D.; Rao, V.; Kronauge, J.; Croop, J. Characterization of multidrug-resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry, 1995, 34, 12210-12220.
39. 99mTc-Sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance, in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl. Med. Comm., 1995, 16, 253-257.
40. Ballinger, J.R.; Sheldon, K.M.; Boxen, I.; Erlichman, C.; Ling, V. Differences between accumulation of Tc-99m-MIBI and Tl-201-thallous chloride in tumor cells, Role of P-glycoprotein. Q. J. Nucl. Med., 1995, 39,122-128.
41. Cordobes, M.; Starzec, A.; Delmon-Moingeon, L.; Blanchot, C.; Kouyoumdjian, J-C.; Prevost, G.; Caglar, M.; Moretti, J-L. Technetium-99m-Sestamibi uptake by human benign and malignant breast tumor cells, correlation with mdr gene expression. J. Nucl. Med., 1996, 37, 286-289.
42. Luker, G.; Rao, V.; Crankshaw, C.; Dahlheimer, J.; Piwnica-Worms, D. Characterization of phosphine complexes of technetium (III) as transport substrates of the multidrug resistance (MDR1) P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier. Biochemistry, 1997, 36, 14218-14227.
43. Bosch, I.; Crankshaw, C.; Piwnica-Worms, D.; Croop, J. Characterization of functional assays of P-glycoprotein transport activity. Leukemia, 1997, 11, 1131-1137.
44. Luker, G.D.; Fracasso, P.M.; Dobkin, J.; Piwnica-Worms, D. Modulation of the multidrug resistance P-glycoprotein, detection with Tc-99m-Sestamibi in vivo. J. Nucl. Med., 1997, 38,369-372.
45. Chen, C.; Meadows, B.; Regis, J.; Kalafsky, G.; Fojo, T.; Carrasquillo, J.; Bates, S. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m-Sestamibi. Clin. Cancer Res., 1997, 3, 545-552.
46. Barbarics, E.; Kronauge, J.; Cohen, D.; Davison, A.; Jones, A.; Croop, J. Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res 1998, 58, 276-282.
47. Luker G, Nilsson K, Covey D, Piwnica-Worms D, MDR1 P-glycoprotein enhances esterification of plasma membrane cholesterol. J Biol Chem 1999, 274, 6979-6991.
48. Peck, R.; Hewett, J.; Harding, M.; Wang, Y.; Chaturvedi, P.; Bhatnagar, A.; Ziessman, H.; Atkins, F.; Hawkins, M. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J. Clin. Oncol., 2001, 19, 3130-3141.
49. Pichler, A.; Prior, J.; Piwnica-Worms, D.; Imaging reversal of multidrug resistance in living mice with bioluminescence, MDR1 P-glycoprotein transports coelenterazine. Proc. Natl. Acad. Sci. USA, 2004, 101, 1702-1707.
50. Agrawal, M.; Abraham, J.; Balis, F.; Edgerly, M.; Stein, W.; Bates, S.; Fojo, T.; Chen, C. Increased Tc-99m-Sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin. Cancer Res., 2003, 9, 650-656.
51. Crankshaw, C.; Piwnica-Worms, D. Tc-99m-Sestamibi may be a transport substrate of the human multidrug resistance-associated protein (MRP). J. Nucl. Med., 1996, 37, 247P.
52. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br. J. Cancer, 1998, 77, 353-358.
53. Moretti, J.L.; Duran Cordobes, M.; Starzec, A.; de Beco, V.; Vergote, J.; Benazzouz, F.; Boissier, B.; Cohen, H.; Safi, N.; Piperno-Neumann, S.; Kouyoumdjian, J.C. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells. J. Nucl. Med., 1998, 39, 1214-1218.
54. Piwnica-Worms, D.; Kronauge, J. Tc-99m-EIBI is a transport substrate for the multidrug resistance (MDR) P-glycoprotein. J. Nucl. Med., 1994, 35, 230P.
55. Herman, L.W.; Sharma, V.; Kronauge, J.F.; Barbarics, E.; Herman, L.A.; Piwnica-Worms, D. Novel hexakis(areneisonitrile) technetium(I) complexes as radioligands targeted to the multidrug resistance P-glycoprotein. J. Med. Chem. 1995, 38, 2955-2963.
56. Jurisson, S.; Berning, D.; Jia, W.; Ma, D-S. Coordination compounds in nuclear medicine. Chem. Rev., 1993, 93, 1137-1156.
57. Deutsch, E.; Vanderheyden, J-L.; Gerundini, P.; Libson, K.; Hirth, W.; Colombo, F.; Savi, A.; Fazio, F. Development of non-reducible technetium-99m(III) cations as myocardial perfusion imaging agents, initial experience in humans. J. Nucl. Med., 1987, 28, 1870-1880.
58. Rossetti, C.; Vanoli, G.; Paganelli, G.; Kwiatkowski, M.; Zito, F.; Colombo, F.; Bonino, C.; Carpinelli, A.; Casati, R.; Deutsch, K. Human biodistribution, dosimetry and clinical use of technetium(III)-99m-Q12. J. Nucl. Med., 1994, 35, 1571-1580.
59. Crankshaw, C.; Marmion, M.; Luker, G.; Rao, V.; Dahlheimer, J.; Burleigh, B.; Webb, E.; Deutsch, K.; Piwnica-Worms, D. Novel Tc(III)-Q-complexes for functional imaging of the multidrug resistance (MDR1) P-glycoprotein. J. Nuc. Med., 1998, 39, 77-86.
60. Jurisson, S.S.; Dancey, K.; McPartlin, M.; Tasker, P.A.; Deutsch, E. Synthesis, characterization, and electrochemical properties of technetium complexes containing both tetradentate Schiff base and monodentate tertiary phosphine ligands, single-crystal structure of trans-(N,N'-ethylenebis(acetylacetone iminato))bis (triphenylphosphine)technetium(III) hexafluorophosphate. Inorg. Chem., 1984, 23, 4743-4749.
61. Kelly, J.; Forster, A.; Higley, B.; Archer, C.; Booker, F.; Canning, L.; Chiu, K.; Edwards, B.; Gill, H.; McPartlin, M.; et al., Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J. Nucl. Med., 1993, 34,222-227.
62. Ballinger, J.R.; Bannerman, J.; Boxen, I.; Firby, P.; Hartman, N.G.; Moore, M.J. Technetium-99m-Tetrofosmin as a substrate for P-glycoprotein, in vitro studies in multidrug-resistant breast tumor cells. J. Nucl. Med., 1996, 37, 1578-1582.
63. - in aqueous solution and its reaction with a bifunctional ligand. J. Am. Chem. Soc., 1998, 120, 7987-7988.
64. 99mTc(I)-tricarbonyl complexes containing isonitrile and phosphine ligands. J. Nucl. Med., 2000, 41, 40P.
65. Dyszlewski, M.; Blake, H.; Dahlheimer, J.; Pica, C.; Piwnica-Worms, D. Characterization of a novel Tc-99m-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity. Mol. Imaging, 2002, 1, 24-35.
66. 99mTc-tetrofosmin in rats. J. Nucl. Med., 2004, 45, 2095-2101.
67. +. J. Nucl. Med., 2008, 49, 1336-1344.
68. Wolohan, P.; Reichert, D. Molecular modeling of hexakis(areneisonitrile)technetium(I), tricarbonyl-cyclopentadienyl technetium and technetium(V)-oxo complexes, MM3 parameter development and prediction of biological properties. J. Mol. Graph Model., 2007, 25, 616-632.
69. Baes, C.; Mesmer, R. The Hydrolysis of Cations. Wiley Interscience, NewYork, 1976, pp. 318-319.
70. Moerlein, S.; Welch, M. The chemistry of gallium and indium as related to radiopharmaceutical production. Int. J. Nucl. Med. Biol., 1981, 8,277-287.
71. Sharma, V.; Beatty, A.; Goldberg, D.E.; Piwnica-Worms, D. Structure of novel antimalarial gallium(III) complex with selectivity against chloroquine-resistant P. falciparum. Chem. Commun., 1997, 2223-2224.
72. Harris, W.R.; Pecoraro, V.L. Thermodynamic binding constants for gallium transferrin. Biochemistry, 1983, 22, 292-299.
73. Sun, Y.; Anderson, C.J.; Pajeau, T.S.; Reichert, D.E.; Hancock, R.D.; Motekaitis, R.J.; Martell, A.E.; Welch, M.J. Indium (III) and gallium (III) complexes of bis(aminoethanethiol) ligands with different denticities, stabilities, molecular modeling, and in vivo behavior. J. Med. Chem., 1996, 39,458-470.
74. Wong, E.; Liu, S.; Lugger, T.; Hahn, F.E.; Orvig, C. Hexadentate N4O2 amine phenol complexes of gallium and indium. Inorg. Chem., 1995, 34, 93-101.
75. Yang, L.W.; Liu, S.; Wong, E.; Rettig, S.J.; Orvig, C. Complexes of trivalent metal ions with potentially heptadentate N4O3 Schiff base and amine phenol ligands of variable rigidity. Inorg. Chem., 1995, 34, 2164-2178.
76. Sarma, B.D.; Bailar, J.C. The stereochemistry of metal complexes with polydentate ligands. Part I. J. Am. Chem. Soc., 1955, 77, 5476-5480.
77. Sarma BD, Ray KR, Sievers RE, Bailar JC, The stereochemistry of metal chelates with multidentate ligands. Part II. J. Am. Chem. Soc., 1964, 86,14-16.
78. Tweedle, M.F.; Wilson, L.J. Variable spin iron(III) chelates with hexadentate ligands derived from triethylenetetramine and various salicyaldehydes. J. Am. Chem. Soc., 1976, 98, 4824-4834.
79. +. J. Nucl. Med., 1993, 34, 1127-1131.
80. Tsang, B.; Mathias, C.; Fanwick, P.; Green,.M. Structure-distribution relationship for metal-labelled myocardial imaging agents, Comparison of a series of cationic gallium(III) complexes with hexadentate bis(salicylaldimine) ligands. J. Med. Chem., 1994, 37, 4400-4406.
81. Sharma, V.; Beatty, A.; Wey, S-P.; Dahlheimer, J.; Pica, C.; Crankshaw, C.; Bass, L.; Green, M.; Welch, M.; Piwnica-Worms, D. Novel gallium(III) complexes transported by MDR1 P-glycoprotein, potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo. Chem. Biol., 2000, 7,335-343.
82. Sharma, V.; Crankshaw, C.; Piwnica-Worms, D. Effects of multidrug resistance (MDR1) P-glycoprotein expression levels and coordination metal on the cytotoxic potency of multidentate (N4O2) ethylenediamine-bis[propyl(R-benzylimino)]metal(III) cations. J. Med. Chem., 1996, 39, 3483-3490.
83. Sharma, V.; Wey, S.P.; Bass, L.; Crankshaw, C.L.; Green, M. A.; Welch, M.J.; Piwnica-Worms, D. Monocationic N4O2 Schiff-Base phenolate complexes of gallium(III), novel PET imaging agents of the human multidrug resistance (MDR1) P-glycoprotein. J. Nucl. Med., 1996, 37,51P.
84. Sharma, V.; Prior, J.; Belinsky, M.; Kruh, G.; Piwnica-Worms, D. Characterization of a gallium-67/gallium-68 radiopharmaceutical for SPECT and PET imaging of MDR1 P-glycoprotein transport activity in vivo, Validation in multidrug resistant tumors and at the blood-brain barrier. J. Nucl. Med., 2005, 46, 354-364.
85. Sharma, V. Radiopharmaceuticals for assessment of multidrug resistance P-glycoprotein-mediated drug transport activity. Bioconjug. Chem., 2004, 15, 1464-1474.
86. Del Vecchio, S.; Ciarmiello, A.; Potena, M. I.; Carriero, M.V.; Mainolfi, C.; Botti, G.; Thomas, R.; Cerra, M.; D'Aiuto, G.; Tsuruo, T.; Salvatore, M. In vivo detection of multidrug resistance (MDR1) phenotype by technetium-99m-sestamibi scan in untreated breast cancer patients. Eur. J. Nucl. Med., 1997, 24,150-159.
87. Del Vecchio, S.; Ciarmiello, A.; Pace, L.; Potena, M.; Carriero, M.; Mainolfi, C. R. T.; D'Aiuto, G.; Tsuruo, T.; Salvatore, M. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J. Nucl. Med., 1997, 38, 1348-1351.
88. Bom, H.; Kim, Y.; Lim, S.; Park, K. Dipyridamole modulated Tc-99m-sestamibi (mibi) scintigraphy, a predictor of response to chemotherapy in patients with small cell lung cancer. J. Nucl. Med., 1997, 38, 240P.
89. Kostakoglu, L.; Elahi, N.; Kirarli, P.; Ruacan, S.; Sayek, S.; Baltali, E.; Sungur, A.; Hayran, M; Bekdik, C. Clinical validation of the influence of P-glycoprotein on technetium-99m-Sestamibi uptake in malignant tumors. J. Nucl. Med., 1997, 38, 1003-1008.
90. Kostakoglu, L.; Kirath, P.; Ruacan, S.; Hayran, M.; Emri, S.; Ergun, E.; Bekdik, C. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J. Nucl. Med., 1998, 39,228-234.
91. Ciarmiello, A.; Del Vecchio, S.; Silvestro, P.; Potena, M.I.; Carriero, M.V.; Thomas, R.; Botti, G.; D'Aiuto, G.; Salvatore, M. Tumor clearance of technetium-99m-Sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J. Clin. Oncol., 1998, 16, 1677-1683.
92. Fukumoto, M.; Yoshida, D.; Hayase, N.; Kurohara, A.; Akagi, N.; Yoshida,.S. Scintigraphic prediction of resistance to radiation and chemotherapy in patients with lung carcinoma, technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography study. Cancer, 1999, 86, 1470-1479.
93. Nagamachi, S.; Jinnouchi, S.; Ohnishi, T.; Nakahara, H.; Flores, L.; Tamura, S.; Tokogami, K.; Kawano, H.; Wakisaka, S. The usefulness of Tc-99m-MIBI for evaluating brain tumors, comparative study with Tl-201 and relation with P-glycoprotein. Clin. Nucl. Med., 1999, 24, 765-772.
94. Kao, C.; Hsieh, J.; Tsai, S.; Ho, Y.; Changlai, S.; Lee, J. Paclitaxel-based chemotherapy for non-small cell lung cancer, predicting the response with 99mtc-tetrofosmin chest imaging. J. Nucl. Med., 2001, 42, 17-20.
95. Shiau, Y.; Tsai, S.; Wang, J.; Ho, Y.; Ho, S.; Kao, C. Technetium-99m tetrofosmin chest imaging related to p-glycoprotein expression for predicting the response with paclitaxel-based chemotherapy for non-small cell lung cancer. Lung Cancer, 2001, 179, 197-207.
96. Sciuto, R.; Pasqualoni, R.; Bergomi, S.; Petrilli, G.; Vici, P.; Belli, F.; Botti, C.; Mottolese, M.; Maini, C. Prognostic value of 99mTc-Sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy. J. Nucl. Med., 2002, 43,745-751.
97. Shih, C.; Shiau, Y.; Wang, J.; Ho, S.; Kao, A. Using technetium-99m tetrofosmin chest imaging to predict taxol-based chemotherpy response in non-small cell lung cancer but not related to lung resistance protein expression. Lung, 2003, 181,103-111.
98. Ding, H.; Huang, W.; Tsai, C.; Change, C.; Kao, A. Usefulness of technetium-99m tetrofosmin liver imaging to detect hepatocellular carcinoma and related to expression of P-glycoprotein or multidrug resistance associated protein - a preliminary report. Nucl. Med. Biol., 2003, 30, 471-475.
99. Ak, I.; Gulbas, Z.; Ocak, S.; Kaya, E.; Alatas, F.; Vardareli, E.; Metintas, M. TC-99m MIBI SPECT imaging in patients with lung carcinoma, is it a functional probe of multidrug resistance genes? J. Comput. Assist. Tomogr., 2007, 31,795-799.
100. Pace, L.; Catalano, L.; Del Vecchio, S.; De Renzo, A.; Fonti, R.; Salvatore, B.; Andretta, C.; Di Nuzzo, C.; Rotoli, B.; Salvatore, M. Washout of [99mTc]Sestamibi in predicting response to chemotherapy in patients with multiple myeloma. Q J. Nucl. Med. Mol. Imaging, 2005, 49, 281-285.
101. 99mTc-MIBI imaging in patients with lung cancer. J. Nucl. Med., 2001, 42, 1476-1483.
102. Chen, W.; Luker, K.; Dahlheimer, J.; Pica, C.; Luker, G.; Piwnica-Worms, D. Effects of MDR1 and MDR3 P-glycoproteins, MRP1 and BCRP/MXR/ABCP on transport of Tc-99m-Tetrofosmin. Biochem. Pharmacol., 2000, 60, 413-426.
103. Duan, X.Y.; Wang, J.S.; Liu, M.; Guo, Y.M. Technetium-99m-hexakis-2-methoxyisobutylisonitrile scintigraphy and multidrug resistance-related protein expression in human primary lung cancer. Ann. Nucl. Med., 2008, 22, 49-55.
104. Mohan, H.K.; Miles, K.A. Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer, systematic review and meta-analysis. J. Nucl. Med., 2009, 50, 376-381.
105. Bell, D.R.; Trent, J.M.; Willard, H.F.; Riordan, J.R.; Ling, V.Chromosomal location of human P-glycoprotein gene sequences. Cancer Genet Cytogenet., 1987, 25,141-148.
106. Ieiri, I.; Takane, H.; Otsubo, K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin. Pharmacokinet., 2004, 43, 553-576.
107. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H.; Brockmoller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M. Functional polymorphisms of the human multidrug-resistance gene, multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA, 2000, 97, 3473-3478.
108. Mickley, L.A.; Lee, J.S.; Weng, Z.; Zhan, Z.; Alvarez, M.; Wilson, W.; Bates, S.E.; Fojo, T. Genetic polymorphism in MDR-1, a tool for examining allelic expression in normal cells, unselected and drugselected cell lines, and human tumors. Blood, 1998, 91, 1749-1756.
109. Kerb, R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett., 2006, 234, 4-33.
110. Wong, M.; Evans, S.; Rivory, L.; Hoskins, J.; Mann, G.; Farlow, D.; Clarke, C.; Balleine, R.; Gurney, H. Hepatic technetium-99m labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin. Pharmacol. Ther., 2005, 77, 33-42.
111. Pusztai, L.; Wagner, P.; Ibrahim, N.; Rivera, E.; Theriault, R.; Booser, D.; Symmans, F.; Wong, F.; Blumenschein, G.; Fleming, D.; Rouzier, R.; Boniface, G.; Hortobagyi, G. N. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer, 2005, 104, 682-691.
112. Abraham, J.; Edgerly, M.; Wilson, R.; Chen, C.; Rutt, A.; Bakke, S.; Robey, R.; Dwyer, A.; Goldspiel, B.; Balis, F. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin. Cancer Res., 2009, 15, 3574-3582.
113. Sasajima T.; Shimada, N.; Naitoh, Y.; Takahashi, M.; Hu, Y.; Satoh, T.; Mizoi, K. (99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors. Int. J. Cancer, 2007, 121, 2637-2645.
114. Drozdzik, M.; Bialecka, M.; Mysliwiec, K.; Honczarenko, K.; Stankiewicz, J.; Sych, Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene, a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics, 2003, 13, 259-263.
115. Furuno, T.; Landi, M.; Ceroni, M.; Caporaso, N.; Bernucci, I.; Nappi, G.; Martignoni, E.; Scaeffeler, E.; Eichelbaum, M.; Schwab, M. Expression polymorphism of the blood-brain barrier component p-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics, 2002, 12, 529-534.
116. Bartels, A.; Willemsen, A.; Kortekaas, R.; deJong, B.; deVries, R.; deKlerk, O.; vanOostrom, J.; Portman, A.; Leenders, K. Decreased blood-brain barrier p-glycoprotein function in the progression of Parkinson's disease, PSP, and MSA. J. Neural. Transm., 2008, 115, 1001-1009.
117. Smyth, M.J.; Krasovskis, E.; Sutton, V.R.; Johnstone, R.W. The drug efflux protein P-glycoprotein additionally protects drugresistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl. Acad. Sci. USA, 1998, 95, 7024-7029.
118. Tainton, K.; Smyth, M.; Jackson, J.; Tanner, J.; Cerruti, L.; Jane, S.D. P.K.; Johnstone, R. Mutational analysis of P-glycoprotein, suppression of caspase activation in the absence of ATP dependent drug efflux. Cell Death Differ., 2004, 11, 1028-1037.
119. Schlachestzki, F.; Pardridge, W. P-glycoprotein and cavolin-1-alpha in endothelium and astrocytes of primate brain. Neuroreport, 2003, 14, 2041-2046.
120. Lee, G.; Schlichter, L.; Bendayan, M.; Bendayan, R. Functional expression of P-glycoprotein in rat brain microglia. J. Pharmacol. Exp. Ther., 2001, 299, 204-212.
121. Volk, H.; Burkhardt, K.; Potschka, H.; Chen, J.; Becker, A.; Loscher, W. Neuronal expression of the drug efflux transporter P-glycoprotein in rat hippocampus after limbic seizures. Neuroscience, 2004, 123, 751-759.
122. Volk, H.; Potschka, H.; Loscher, W. Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J. Histochem. Cytochem., 2005, 53, 517-531.
123. McKhann, G.; Drachman, D.; Folstein, M. Clinical diagnosis of Alzheimer's disease, Report of the NINCDS-ADRDA work group under the auspices of the department of health and human services task force on Alzheimer's disease Neurology, 1984, 34, 939-944.
124. Weiner, M. Alzheimer's disease, diagnosis and treatment. Harvard Rev. Psychiatry, 1997, 4, 306-316.
125. Yanker, B. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron, 1996, 16,921-932.
126. Lansbury, P.J. A reductionist view of Alzheimer's disease. Acc Chem. Res., 1996, 29, 317-321.
127. Teller, J. Presence of soluble amyloid ß-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med., 1996, 2, 93-95.
128. Games, D. Alzheimer-type neuropathology in transgenic mice overexpressing V717F ß-amyloid precursor protein. Nature, 1995, 373,523-527.
129. Hsiao, K.; Chapman, P.; Nilsen, S.; Eckman, S.; Harigaya, Y.; Younkin, S.; Yang, F.; Cole, G. Correlative memory deficits, Aß elevation, and amyloid plaques in transgenic mice. Science, 1996, 274, 99-102.
130. Farris, W.; Mansourian, S.; Chang, Y.; Lindsley, L.; Eckman, E.A.; Frosch, M.P.; Eckman, C. B.; Tanzi, R. E.; Selkoe, D. J.; Guenette, S. Insulin-degrading enzyme regulates the levels of insulin, amyloid, and -amyloid precursor protein intyracellular domain in vivo. Proc. Natl. Acad. Sci. USA, 2003, 100, 4162-4167.
131. Iwata, N.; Mizukami, H.; Shirotani, K.; Takaki, Y.; Muramatsu, S.; Lu, B.; Gerard, N.; Gerard, C.; Ozawa, K.; Saido, T. Presynaptic localization of neprilysin contributes to efficient clearance of amyloidbeta peptide in mouse brain. J. Neurosci., 2004, 24, 991-998.
132. Weller, R.; Massey, A.; Newman, T.; Hutchings, M.; Kuo, Y.; Roher, A. Cerebral amyloid angiopathy, amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am. J. Pathol., 1998, 153,725-733.
133. DeMattos, R.; Bales, K.; Cummins, D.; Paul, S.; Holtzman, D. Brain to plasma amyloidefflux, a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science, 2002, 295, 2264-2267.
134. Shibata, M.; Yamada, S.; Kumar, S.; Calero, M.; Bading, J.; Frangione, B.; Holtzman, D.; Miller, C.; Strickland, D.; Ghiso, J. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest, 2000, 106,1489-1499.
135. Zlokovic, B. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci., 2005, 28, 202-208.
136. Deane, R.; Wu, Z.; Sagare, A.; Davis, J.; Du Yan, S.; Hamm, K.; Xu, F.; Parisi, M.; LaRue, B.; Hu, H. LRP/amyloid peptide interaction mediates differential brain efllux of A isoforms. Neuron, 2004, 43, 333-344.
137. Zlokovic, B.; Yamada, S.; Holtzman, D.; Ghiso, J.; Frangione, B. Clearance of amyloid pepitde from brain, transport or metabolism? Nat. Med., 2000, 6,718-719.
138. Vogelgesang, S.; Cascorbi, I.; Schroeder, R.; Pahnke, J.; Kroemer, H.; Siegmund, W.; Kunert-Keil, C.; Walker, L.; Warzok, R. Deposition of Alzheimer's amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics, 2002, 12, 535-541.
139. Cirrito, J.R.; Deane, R.; Fagan, A.M.; Spinner, M.L.; Parsadanian, M.; Finn, M.B.; Jiang, H.; Prior, J.L.; Sagare, A.; Bales, K.R. P-glycoprotein deficiency at the blood-brain barrier increases amyloidbeta deposition in an Alzheimer's disease mouse model. J. Clin. Invest, 2005, 115, 3285-3290.
140. Kuhnke, D.; Jedlitschky, G.; Grube, M.; Krohn, M.; Jucker, M.; Mosyagin, I.; Cascorbi, I.; Walker, L.C.; Kroemer, H.K.; Warzok, R.W. MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol., 2007, 17, 347-353.
141. Marzolini, C.; Paus, E.; Buclin, T.; Kim, R. Polymorphisms in human MDR1 (P-glycoprotein), recent advances and clinical relevance. Clin. Pharmacol. Ther., 2004, 75,13-33.